Doxorubicin and cyclophosphamide mode of chemotherapy-related cardiomyopathy: Review of preclinical model

Over the past 70 years, there has been extensive research focused on preventing chemotherapy-related cardiovascular complications. However, the current state of cardio-oncology research has raised more questions than answers. Experimental studies often present data that are difficult to compare and, at times, contradictory. One notable limitation in translating experimental findings to clinical practice is the reliance on models that administer only one chemotherapeutic drug to experimental animals, despite the common use of multidrug cancer treatments in real clinical settings. This article aims to discuss our own experience in modeling an experimental rat model of cardiomyopathy induced by the administration of two chemotherapeutic drugs, doxorubicin (adriamycin) and cyclophosphamide (AC mode of chemotherapy) - Avagimyan A., et al model, along with a subsequent review of morphological changes based on our personal archive. Copyright © 2024. Published by Elsevier Inc.

Авторы
Avagimyan A. , Kakturskiy L. , Pogosova N. , Ottaviani G. , Rizzo M. , Sarrafzadegan N.
Издательство
Elsevier Inc.
Номер выпуска
1
Язык
Английский
Статус
Опубликовано
Том
50
Год
2025
Организации
  • 1 Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  • 2 A.P. Avtsyn Research Institute of Human Morphology, Moscow, Russian Federation
  • 3 National Medical Research Centre of Cardiology after acad. E. I. Chazov, Moscow, Russia
  • 4 Peoples' Friendship University of Russia after Patrice Lumumba (RUDN), Moscow, Russia
  • 5 Lino Rossi Research Center, Università degli Studi di Milano, Milan, Italy
  • 6 Università degli Studi di Palermo, Palermo, Italy
  • 7 University of British Columbia, Vancouver, Canada
Ключевые слова
Cardiomyopathy; Cardiotoxicity; Cyclophosphamide; Doxorubicin; Model
Цитировать
Поделиться

Другие записи